Cydan II, Inc.

Cydan II, Inc.

Cydan II, Inc.

Overview
Headquarters

700 TECHNOLOGY SQUARE 3RD FLOOR CAMBRIDGE MA 02139

Type of Company

Private

Employees (Worldwide)

1 - 10

Industries

Wholesale: Consumer Non-Durables/Sundries
Hospitals & Patient Services
Medical Support Services
Biotechnology
Pharmaceuticals
Medical Products & Equipment
Holding Companies

Company Description

Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA.

Executives & Employees

Co-Founder

Chief Business Officer

Chief Medical Officer

Senior Director of Preclinical Research

Senior Vice President of Development

Vice President of Preclinical Development

Vice President, Preclinical Development

Vice President, Preclinical Translation

Office Manager

Board of Directors

General Partner, Washington DC at New Enterprise Associates

Co-Founder at Alexandria Real Estate Equities, Inc.

Managing Director at Longitude Capital Management Co. LLC

Paths to Cydan II, Inc.
Potential Connections via
Relationship Science
You
Cydan II, Inc.
Recent Transactions
Details Hidden

Cydan II, Inc. raised money in a private placement transaction

Investments
Details Hidden

Imara, Inc. develops novel therapeutics for patients with sickle cell disease. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.

Investors
Details Hidden

Pfizer Venture Investments focuses on investments in emerging companies that are developing or compounding technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry. The firm focuses on healthcare related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT, and other technologies impacting drug discovery and development.Pfizer Venture Investments may invest up to $10 million per round in selected companies at any stage of development including start-ups, spinouts and consortia investments with emphasis on growth stage opportunities. Other investments, including fund investing, spinout opportunities and PIPEs are also be considered as appropriate. They have the ability to lead or join a syndicate of investors and they take seat on the board of directors.

Details Hidden

Longitude Capital invests in growth capital investments in biotechnology and medical technology. They consider companies across all therapeutic indications and stages of development.

Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cydan II, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cydan II, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Cydan II, Inc..